Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State.
Fayfman M, Pasquel FJ, Umpierrez GE.
Med Clin North Am. 2017 May;101(3):587-606. doi: 10.1016/j.mcna.2016.12.011.
Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.
Umpierrez G, Korytkowski M.
Nat Rev Endocrinol. 2016 Apr;12(4):222-32. doi: 10.1038/nrendo.2016.15. Epub 2016 Feb 19.
Pathophysiology of diabetes mellitus.
Guthrie RA, Guthrie DW.
Crit Care Nurs Q. 2004 Apr-Jun;27(2):113-25. doi: 10.1097/00002727-200404000-00003.
Diabetic ketoacidosis fluid management in children: systematic review and meta-analyses.
Hamud AA, Mudawi K, Shamekh A, Kadri A, Powell C, Abdelgadir I.
Arch Dis Child. 2022 Nov;107(11):1023-1028. doi: 10.1136/archdischild-2022-324042. Epub 2022 Jun 23.
Management of Hyperosmolar Hyperglycaemic State (HHS) in Adults: An updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group.
Mustafa OG, Haq M, Dashora U, Castro E, Dhatariya KK; Joint British Diabetes Societies (JBDS) for Inpatient Care Group.
Diabet Med. 2023 Mar;40(3):e15005. doi: 10.1111/dme.15005. Epub 2022 Dec 21.
Clinical and prognostic differences in diabetic ketoacidosis between type 2 and type 1 diabetes.
Tapia Sanchiz MS, Navas Moreno V, Lopez Ruano M, Martínez Otero C, Carrillo López E, Sager La Ganga C, Raposo López JJ, Amar S, González Castañar S, Arranz Martín JA, Marazuela M, Sebastian-Valles F.
Med Clin (Barc). 2025 Jul;165(1):106973. doi: 10.1016/j.medcli.2025.106973. Epub 2025 May 15.
Hyperosmolar Hyperglycemic State.
Stoner GD.
Am Fam Physician. 2017 Dec 1;96(11):729-736.
Hyperosmolar Hyperglycemic Syndrome.
Adeyinka A, Kondamudi NP.
2023 Aug 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
Phenotypic heterogeneity of type 2 diabetes and risks of all-cause and cause-specific mortality.
Qiu Z, Qian F, Liu J, Li R, Yu H, Wang Y, Zhang X, Geng T, Yu X, Franco OH, Pan A, Zhou M, Huang K, Liu G.
Cell Rep Med. 2025 Nov 18;6(11):102367. doi: 10.1016/j.xcrm.2025.102367. Epub 2025 Sep 19.
Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21–liraglutide Study Group investigators and contributors.
Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1.
